| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 7,529 | -56,382 |
| Depreciation and amortization | 9,402 | 6,371 |
| Share-based compensation | 10,309 | 7,067 |
| Non-cash royalty revenue | 77,535 | 48,387 |
| Non-cash interest expense | 38,666 | 25,681 |
| Loss on disposal of assets, net | -936 | -929 |
| Gain from deconsolidation of mink therapeutics, inc | 100,924 | - |
| Unrealized loss on long-term investments | -20,096 | - |
| Gain on lease terminations | 0 | 0 |
| Other, net | 200 | -255 |
| Accounts receivable | 49 | 232 |
| Prepaid expenses | -1,160 | -980 |
| Accounts payable | 26,840 | 12,706 |
| Deferred revenue | 1 | 1 |
| Accrued liabilities and other current liabilities | 13,435 | 4,230 |
| Other operating assets and liabilities | 10,243 | -941 |
| Net cash used in operating activities | -60,577 | -45,840 |
| Purchases of plant and equipment | 6 | 6 |
| Proceeds from sale of plant and equipment | 358 | 282 |
| Proceeds from sale of long-term investment | 62 | 62 |
| Net cash provided by investing activities | 414 | 338 |
| Net proceeds from sale of equity | 27,525 | 18,560 |
| Net proceeds from sale of subsidiary shares in private placement | 0 | 0 |
| Proceeds from ligand purchase agreement, net of expenses | 0 | 0 |
| Proceeds from employee stock purchases and option exercises | 122 | 44 |
| Proceeds from the issuance of long-term debt, net | 2,500 | 2,500 |
| Impact to cash resulting from deconsolidation of a subsidiary | 1,682 | - |
| Purchase of treasury shares to satisfy tax withholdings | 87 | 87 |
| Payment of long-term debt | 2,500 | 2,500 |
| Payment of finance lease obligation | 4,659 | 3,981 |
| Net cash provided by financing activities | 21,219 | 14,536 |
| Effect of exchange rate changes on cash | 43 | 63 |
| Net decrease in cash, cash equivalents and restricted cash | -38,901 | -30,903 |
| Cash and cash equivalents at beginning of period | 44,071 | - |
| Cash and cash equivalents at end of period | 5,170 | - |
AGENUS INC (AGEN)
AGENUS INC (AGEN)